



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION



JAK2 JH2 Domain (human, recombinant; aa 513-827) - Biotinylated Item No. 42273

Overview and Properties


Synonyms: Janus-Associated Kinase 2, JTK10, Tyrosine-protein Kinase JAK2
Source: Recombinant human C-terminal His-tagged biotinylated JAK2 JH2 domain expressed in insect cells (Sf9)
Amino Acids: 513-827
Uniprot No.: O60674
Molecular Weight: 39 kDa
Storage: -80°C (as supplied); avoid freeze/thaw
Stability: ≥6 months
Purity: ≥90% estimated by SDS-PAGE
Supplied in: 40 mM Tris-HCl, pH 8.0, 300 mM sodium chloride, 2.2 mM potassium chloride, 20% glycerol, and 0.2 mM TCEP

Protein


Concentration: *batch specific* mg/ml
Specific Activity: *batch specific* U/mg

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



SDS-PAGE Analysis of JAK2 JH2 Domain. This protein has a calculated molecular weight of 39 kDa.



Biotin-Avidin Analysis of JAK2 JH2 Domain.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

PRODUCT INFORMATION

Description

JAK2 is a non-receptor tyrosine kinase that has roles in immune signaling.^{1,2} It is composed of N-terminal FERM and SH2 domains, a regulatory JH2 pseudokinase domain, and a C-terminal JH1 kinase domain. It is widely expressed and associates with class I and class II cytokine receptors at the plasma membrane.^{3,4} Activation of these cytokine receptors activates JAK2 and induces its dimerization and kinase activity, leading to JAK2 phosphorylation of STAT transcription factors and transcription of immune-related target genes. JAK2 signaling is inhibited by the suppressor of cytokine signaling (SOCS) proteins SOCS1 and SOCS3.^{5,6} Gain-of-function mutations in JAK2, such as JAK2^{V617F} in the JH2 domain, are associated with various blood disorders, including leukemias and myeloproliferative neoplasms.⁴ Cayman's JAK2 JH2 Domain (human, recombinant; aa 513-827) - Biotinylated protein can be used for pull-down assays and has a calculated molecular weight of 39 kDa.

References

1. Leonard, W.J. and O'Shea, J.J. JAKS and STATS: Biological implications. *Annu. Rev. Immunol.* **16**, 293-322 (1998).
2. Haan, C., Kreis, S., Margue, C., et al. Jaks and cytokine receptors—an intimate relationship. *Biochem. Pharmacol.* **72(11)**, 1538-1546 (2006).
3. Parganas, E., Wang, D., Stravopodis, D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. *Cell* **93(3)**, 385-395 (1998).
4. Hubbard, S.R. Mechanistic insights into regulation of JAK2 tyrosine kinase. *Front. Endocrinol. (Lausanne)* **8**, 361 (2018).
5. Kile, B.T. and Alexander, W.S. The suppressors of cytokine signalling (SOCS). *Cell. Mol. Life Sci.* **58(11)**, 1627-1635 (2001).
6. Yoshimura, A. and Yasukawa, H. JAK's SOCS: A mechanism of inhibition. *Immunity* **36(2)**, 157-159 (2012).